Registry-listed formulations

This catalogue entry has no confirmed scientific concept.

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

0 source entries across 0 studies. This list may not include all unresolved or historical entries.

    Success Metrics

    Active Trials
    0(0%)

    Phase Distribution

    Not Applicable
    1
    20%
    Phase 1/2
    1
    20%
    Early Phase 1
    3
    60%

    Phase Distribution

    3

    Early Stage

    1

    Mid Stage

    0

    Late Stage

    Phase Distribution5 total trials
    Early Phase 1First-in-human
    3(60.0%)
    Phase 1/2Combined phases
    1(20.0%)
    N/ANon-phased studies
    1(20.0%)

    Highest Phase Reached

    Phase 1/2

    Trial Status & Enrollment

    Completion Rate

    0.0%

    0 of 0 finished

    Non-Completion Rate

    0.0%

    0 ended early

    Currently Active

    0

    trials recruiting

    Total Trials

    5

    all time

    Status Distribution
    Other(5)

    Detailed Status

    unknown5

    Development Timeline

    Analytics

    Development Status

    Total Trials
    5
    Active
    0
    Success Rate
    N/A
    Most Advanced
    Phase 1/2

    Trials by Phase

    Early Phase 13 (60.0%)
    Phase 1/21 (20.0%)
    N/A1 (20.0%)

    Trials by Status

    unknown5100%

    Recent Activity

    0 active trials
    Showing 5 of 5
    unknownearly_phase_1

    Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

    NCT04626726
    unknownearly_phase_1

    CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

    NCT04626739
    unknownearly_phase_1

    CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

    NCT04626765
    unknownnot_applicable

    Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

    NCT04546906
    unknownphase_1_2

    CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

    NCT02794961

    Clinical Trials (5)

    Showing 5 of 5 trials
    NCT04626726Early Phase 1

    Adult B-ALL Treated by CART Cell Bridging Allogeneic Hematopoietic Stem Cell Transplantation

    Unknown
    NCT04626739Early Phase 1

    CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

    Unknown
    NCT04626765Early Phase 1

    CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

    Unknown
    NCT04546906Not Applicable

    Safety and Efficacy Study of CD22 CAR-T Cells for Relapsed or Refractory Acute Lymphoblastic Leukemia

    Unknown
    NCT02794961Phase 1/2

    CD22 Targeting CAR-T Therapy Against B Cell Hematological Malignancies

    Unknown

    All 5 trials loaded

    Drug Details

    Intervention Type
    Varies by study
    Total Trials
    5